Adicet Bio Inc. (ACET) NASDAQ
$2.33 0.09 (4.02%)
Market Cap: $193.06M
As of 03/28/24 04:00 PM EDT. Market closed.
Adicet Bio Inc. (ACET)
NASDAQ
$2.33
0.09 (4.02%)
Market Cap: $193.06M
As of 03/28/24 04:00 PM EDT. Market closed.
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating ... read more
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicet’s gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
ORBIMED ADVISORS LLC | Director | Jan 25, 2024 | Buy | $2.40 | 3,125,000 | 7,500,000 | 7,526,359 | Jan 26, 2024, 07:14 PM |
GORDON CARL L | Director | Jan 25, 2024 | Buy | $2.40 | 3,125,000 | 7,500,000 | 7,526,359 | Jan 26, 2024, 07:13 PM |
Galimi Francesco | SVP & Chief Medical Officer | Jan 24, 2024 | Option Exercise | $2.40 | 4,957 | 11,897 | 75,501 | Jan 26, 2024, 07:11 PM |
Aftab Blake | Chief Scientific Officer | Jan 24, 2024 | Option Exercise | $2.40 | 3,565 | 8,556 | 42,811 | Jan 26, 2024, 07:10 PM |
Healey Don | Chief Technology Officer | Jan 24, 2024 | Option Exercise | $2.40 | 4,870 | 11,688 | 52,629 | Jan 26, 2024, 07:09 PM |
Harvey Brian Nicholas | Chief Financial Officer | Jan 24, 2024 | Option Exercise | $2.40 | 4,320 | 10,368 | 73,500 | Jan 26, 2024, 07:08 PM |
Schor Chen | President & CEO | Jan 24, 2024 | Option Exercise | $2.40 | 15,290 | 36,696 | 138,471 | Jan 26, 2024, 07:06 PM |
Aftab Blake | Chief Scientific Officer | Oct 12, 2023 | Option Exercise | $1.35 | 7,933 | 10,710 | 46,376 | Oct 16, 2023, 04:11 PM |
Galimi Francesco | SVP & Chief Medical Officer | Oct 02, 2023 | Option Exercise | $1.37 | 8,093 | 11,087 | 80,458 | Oct 03, 2023, 04:24 PM |
Healey Don | Chief Technology Officer | Oct 02, 2023 | Option Exercise | $1.37 | 9,069 | 12,425 | 57,499 | Oct 03, 2023, 04:22 PM |
Schor Chen | President & CEO | Oct 02, 2023 | Option Exercise | $1.37 | 23,208 | 31,795 | 153,761 | Oct 02, 2023, 08:16 PM |
Schor Chen | President & CEO | Sep 28, 2023 | Buy | $1.42 | 5,500 | 7,810 | 182,469 | Oct 02, 2023, 08:16 PM |
Schor Chen | President & CEO | Oct 02, 2023 | Buy | $1.33 | 5,500 | 7,340 | 43,469 | Oct 02, 2023, 08:16 PM |
Schor Chen | President & CEO | Sep 29, 2023 | Sale | $1.36 | 5,500 | 7,481 | 176,969 | Oct 02, 2023, 08:16 PM |
Schor Chen | President & CEO | Sep 28, 2023 | Sale | $1.42 | 5,500 | 7,810 | 37,969 | Oct 02, 2023, 08:16 PM |
DUBIN STEVE | Director | Jun 30, 2023 | Buy | $2.40 | 5,000 | 11,999 | 10,900 | Jun 30, 2023, 04:08 PM |
GORDON CARL L | Director | Jun 27, 2023 | Buy | $2.09 | 875,000 | 1,828,750 | 5,685,259 | Jun 29, 2023, 04:51 PM |
ORBIMED ADVISORS LLC | Director | Jun 27, 2023 | Buy | $2.09 | 875,000 | 1,828,750 | 5,685,259 | Jun 29, 2023, 04:46 PM |
Healey Don | Chief Technology Officer | Feb 15, 2023 | Sale | $7.57 | 4,533 | 34,327 | 66,568 | Feb 17, 2023, 08:22 PM |
Healey Don | Chief Technology Officer | Feb 10, 2023 | Sale | $7.98 | 10,467 | 83,476 | 71,101 | Feb 14, 2023, 04:50 PM |
Aftab Blake | Chief Scientific Officer | Nov 10, 2022 | Sale | $21.00 | 6,967 | 146,307 | 28,209 | Nov 15, 2022, 04:32 PM |
Schor Chen | President & CEO | Nov 10, 2022 | Sale | $20.06 | 30,000 | 601,920 | 53,424 | Nov 15, 2022, 04:31 PM |
Schor Chen | President & CEO | Nov 10, 2022 | Sale | $21.03 | 9,955 | 209,322 | 91,469 | Nov 15, 2022, 04:31 PM |
Schor Chen | President & CEO | Nov 07, 2022 | Sale | $19.05 | 30,000 | 571,488 | 83,424 | Nov 09, 2022, 04:05 PM |
Schor Chen | President & CEO | Nov 02, 2022 | Sale | $18.00 | 500 | 9,000 | 138,237 | Nov 04, 2022, 05:23 PM |
Schor Chen | President & CEO | Nov 03, 2022 | Sale | $18.04 | 24,813 | 447,718 | 113,424 | Nov 04, 2022, 05:23 PM |
Aftab Blake | Chief Scientific Officer | Oct 19, 2022 | Sale | $16.27 | 8,067 | 131,250 | 35,176 | Oct 21, 2022, 04:10 PM |
Aftab Blake | Chief Scientific Officer | Oct 13, 2022 | Option Exercise | $15.92 | 7,933 | 126,293 | 43,243 | Oct 14, 2022, 04:08 PM |
Aftab Blake | Chief Scientific Officer | Oct 12, 2022 | Option Exercise | $7.38 | 3,388 | 25,003 | 52,822 | Oct 14, 2022, 04:08 PM |
Aftab Blake | Chief Scientific Officer | Oct 12, 2022 | Sale | $15.40 | 1,646 | 25,348 | 51,176 | Oct 14, 2022, 04:08 PM |
Schor Chen | President & CEO | Oct 04, 2022 | Option Exercise | $14.22 | 21,288 | 302,715 | 101,424 | Oct 04, 2022, 05:22 PM |
Harvey Brian Nicholas | Chief Financial Officer | Oct 04, 2022 | Option Exercise | $14.22 | 7,096 | 100,905 | 58,816 | Oct 04, 2022, 05:21 PM |
Healey Don | Chief Technology Officer | Oct 04, 2022 | Option Exercise | $14.22 | 7,933 | 112,807 | 55,468 | Oct 04, 2022, 05:20 PM |
Galimi Francesco | SVP & Chief Medical Officer | Oct 04, 2022 | Option Exercise | $14.22 | 7,933 | 112,807 | 62,451 | Oct 04, 2022, 05:18 PM |
Schor Chen | President & CEO | Sep 14, 2022 | Sale | $18.00 | 952 | 17,136 | 138,737 | Sep 16, 2022, 05:51 PM |
Schor Chen | President & CEO | Sep 13, 2022 | Sale | $18.01 | 3,371 | 60,713 | 139,689 | Sep 13, 2022, 04:59 PM |
Schor Chen | President & CEO | Sep 12, 2022 | Sale | $16.77 | 66,947 | 1,122,907 | 143,060 | Sep 13, 2022, 04:59 PM |
Schor Chen | President & CEO | Sep 09, 2022 | Sale | $16.51 | 8,094 | 133,601 | 66,747 | Sep 13, 2022, 04:59 PM |
Schor Chen | President & CEO | Aug 04, 2022 | Option Exercise | $18.25 | 21,288 | 388,506 | 122,712 | Aug 08, 2022, 08:32 PM |
Galimi Francesco | SVP & Chief Medical Officer | Aug 04, 2022 | Option Exercise | $18.25 | 5,533 | 100,977 | 70,384 | Aug 08, 2022, 08:31 PM |
Aftab Blake | Chief Scientific Officer | Aug 04, 2022 | Option Exercise | $18.25 | 5,533 | 100,977 | 49,434 | Aug 08, 2022, 08:29 PM |
Harvey Brian Nicholas | Chief Financial Officer | Aug 04, 2022 | Option Exercise | $18.25 | 4,696 | 85,702 | 65,912 | Aug 08, 2022, 08:27 PM |
Healey Don | Chief Technology Officer | Aug 04, 2022 | Option Exercise | $18.25 | 5,533 | 100,977 | 63,401 | Aug 08, 2022, 08:26 PM |
Aftab Blake | Chief Scientific Officer | Aug 03, 2022 | Sale | $18.00 | 6,968 | 125,424 | 38,967 | Aug 05, 2022, 06:43 PM |
Aftab Blake | Chief Scientific Officer | Aug 01, 2022 | Sale | $16.64 | 6,968 | 115,948 | 45,935 | Aug 03, 2022, 04:16 PM |
Aftab Blake | Chief Scientific Officer | Jul 05, 2022 | Sale | $14.50 | 1,363 | 19,764 | 52,903 | Jul 07, 2022, 05:12 PM |
Galimi Francesco | SVP & Chief Medical Officer | Apr 04, 2022 | Option Exercise | $13.91 | 7,979 | 110,956 | 65,953 | Apr 05, 2022, 06:23 PM |
Galimi Francesco | SVP & Chief Medical Officer | Apr 01, 2022 | Option Exercise | $5.97 | 7,621 | 45,497 | 67,538 | Apr 05, 2022, 06:23 PM |
Galimi Francesco | SVP & Chief Medical Officer | Apr 04, 2022 | Sale | $21.00 | 7,979 | 167,559 | 59,917 | Apr 05, 2022, 06:23 PM |
Galimi Francesco | SVP & Chief Medical Officer | Apr 01, 2022 | Sale | $21.00 | 7,621 | 160,041 | 59,917 | Apr 05, 2022, 06:23 PM |
Jakobovits Aya | Director | Mar 09, 2022 | Sale | $14.00 | 4,000 | 56,000 | 356,345 | Mar 11, 2022, 04:08 PM |
Jakobovits Aya | Director | Feb 16, 2022 | Sale | $14.83 | 4,000 | 59,328 | 358,345 | Feb 17, 2022, 06:10 PM |
Healey Don | Chief Technology Officer | Feb 14, 2022 | Option Exercise | $14.27 | 5,533 | 78,956 | 52,934 | Feb 16, 2022, 09:41 PM |
Aftab Blake | Chief Scientific Officer | Feb 14, 2022 | Option Exercise | $14.27 | 5,533 | 78,956 | 52,903 | Feb 16, 2022, 09:40 PM |
Galimi Francesco | SVP & Chief Medical Officer | Feb 14, 2022 | Option Exercise | $14.27 | 5,533 | 78,956 | 59,917 | Feb 16, 2022, 09:36 PM |
Harvey Brian Nicholas | Chief Financial Officer | Feb 14, 2022 | Option Exercise | $14.27 | 4,696 | 67,012 | 54,608 | Feb 16, 2022, 09:33 PM |
Schor Chen | President & CEO | Feb 14, 2022 | Option Exercise | $14.27 | 21,288 | 303,780 | 149,424 | Feb 16, 2022, 09:31 PM |
Galimi Francesco | SVP & Chief Medical Officer | Jan 28, 2022 | Option Exercise | $11.69 | 5,533 | 64,681 | 49,450 | Feb 01, 2022, 08:50 PM |
Healey Don | Chief Technology Officer | Jan 28, 2022 | Option Exercise | $11.69 | 5,533 | 64,681 | 42,467 | Feb 01, 2022, 08:48 PM |
Aftab Blake | Chief Scientific Officer | Jan 28, 2022 | Option Exercise | $11.69 | 5,564 | 65,043 | 42,436 | Feb 01, 2022, 08:44 PM |
Harvey Brian Nicholas | Chief Financial Officer | Jan 28, 2022 | Option Exercise | $11.69 | 4,696 | 54,896 | 43,304 | Feb 01, 2022, 08:42 PM |
Schor Chen | President & CEO | Jan 28, 2022 | Option Exercise | $11.69 | 21,288 | 248,857 | 122,712 | Feb 01, 2022, 08:40 PM |
GORDON CARL L | Director | Dec 10, 2021 | Option Exercise | $14.00 | 214,285 | 2,999,990 | 242,285 | Dec 14, 2021, 07:06 PM |
ORBIMED ADVISORS LLC | Director | Dec 10, 2021 | Option Exercise | $14.00 | 214,285 | 2,999,990 | 242,285 | Dec 14, 2021, 06:41 PM |
Sinclair Andrew | Director | Dec 08, 2021 | Buy | $14.00 | 500,000 | 7,000,000 | 2,115,385 | Dec 13, 2021, 06:00 PM |
Sinclair Andrew | Director | Dec 08, 2021 | Buy | $14.00 | 500,000 | 7,000,000 | 2,140,721 | Dec 10, 2021, 05:30 PM |
Schor Chen | President & CEO | Jun 16, 2021 | Sale | $10.53 | 16,466 | 173,443 | 89,836 | Jun 21, 2021, 04:25 PM |
Jakobovits Aya | Director | Jun 15, 2021 | Sale | $11.16 | 3,847 | 42,919 | 215,883 | Jun 17, 2021, 06:08 PM |
Galimi Francesco | SVP & Chief Medical Officer | Jun 04, 2021 | Option Exercise | $5.97 | 6,983 | 41,689 | 6,983 | Jun 08, 2021, 09:35 PM |
Schor Chen | President & CEO | May 19, 2021 | Sale | $13.45 | 16,466 | 221,436 | 108,533 | May 21, 2021, 04:34 PM |
Schor Chen | President and CEO | Apr 20, 2021 | Sale | $12.01 | 16,466 | 197,676 | 125,764 | Apr 22, 2021, 04:34 PM |
Schor Chen | President and CEO | Apr 06, 2021 | Sale | $13.04 | 16,466 | 214,700 | 134,746 | Apr 08, 2021, 04:37 PM |
Schor Chen | President and CEO | Mar 30, 2021 | Sale | $12.85 | 16,466 | 211,640 | 149,128 | Apr 01, 2021, 06:48 PM |
Schor Chen | President and CEO | Mar 16, 2021 | Sale | $15.34 | 16,466 | 252,558 | 155,218 | Apr 01, 2021, 06:43 PM |
Schor Chen | President and CEO | Mar 16, 2021 | Sale | $15.34 | 16,466 | 252,558 | 155,218 | Mar 18, 2021, 09:55 PM |
Chimovits Erez | Director | Feb 12, 2021 | Option Exercise | $13.00 | 524,349 | 6,816,537 | 5,243,259 | Feb 18, 2021, 09:44 PM |
GORDON CARL L | Director | Feb 12, 2021 | Option Exercise | $13.00 | 524,349 | 6,816,537 | 5,243,259 | Feb 18, 2021, 09:41 PM |
ORBIMED ADVISORS LLC | Director | Feb 12, 2021 | Option Exercise | $13.00 | 524,349 | 6,816,537 | 5,243,259 | Feb 18, 2021, 09:38 PM |
PureTech Health LLC | 10% Owner | Dec 18, 2019 | Sale | $1.20 | 6,161,531 | 7,393,837 | 2,119,696 | Dec 19, 2019, 05:26 PM |
PureTech Health LLC | 10% Owner | Dec 13, 2019 | Sale | $1.24 | 205,763 | 255,805 | 8,281,227 | Dec 17, 2019, 06:27 PM |
PureTech Health LLC | 10% Owner | Dec 12, 2019 | Sale | $1.25 | 385,884 | 482,316 | 8,486,990 | Dec 12, 2019, 05:59 PM |
PureTech Health LLC | 10% Owner | Dec 11, 2019 | Sale | $1.25 | 59,921 | 74,901 | 8,872,874 | Dec 12, 2019, 05:59 PM |
PureTech Health LLC | 10% Owner | Dec 10, 2019 | Sale | $1.26 | 336,561 | 423,663 | 8,932,795 | Dec 12, 2019, 05:59 PM |
PureTech Health LLC | 10% Owner | Nov 15, 2019 | Sale | $1.25 | 531,040 | 661,941 | 9,269,356 | Nov 19, 2019, 04:25 PM |
Schor Chen | President and CEO | Apr 16, 2018 | Buy | $8.95 | 2,000 | 17,907 | 1,892,363 | Apr 17, 2018, 08:08 AM |
Schor Chen | President and CEO | Apr 11, 2018 | Buy | $9.36 | 2,000 | 18,724 | 1,890,363 | Apr 12, 2018, 07:32 AM |
Schor Chen | President and CEO | Apr 10, 2018 | Buy | $8.46 | 2,000 | 16,915 | 1,888,363 | Apr 11, 2018, 08:06 AM |
SILVERSTEIN JONATHAN | Director | Jan 30, 2018 | Buy | $15.00 | 533,333 | 7,999,995 | 4,830,387 | Jan 30, 2018, 06:42 PM |
ORBIMED ADVISORS LLC | Director | Jan 30, 2018 | Buy | $15.00 | 533,333 | 7,999,995 | 4,830,387 | Jan 30, 2018, 06:41 PM |
PureTech Health LLC | 10% Owner | Jan 30, 2018 | Buy | $15.00 | 233,333 | 3,499,995 | 9,800,396 | Jan 30, 2018, 06:37 PM |
Owner | Relationship | Date | Value($) |
ORBIMED ADVISORS LLC | Director | 01/25/2024 | 7,500,000 |
GORDON CARL L | Director | 01/25/2024 | 7,500,000 |
Galimi Francesco | SVP & Chief Medical Officer | 01/24/2024 | 11,897 |
Aftab Blake | Chief Scientific Officer | 01/24/2024 | 8,556 |
Healey Don | Chief Technology Officer | 01/24/2024 | 11,688 |
Harvey Brian Nicholas | Chief Financial Officer | 01/24/2024 | 10,368 |
Schor Chen | President & CEO | 01/24/2024 | 36,696 |
Aftab Blake | Chief Scientific Officer | 10/12/2023 | 10,710 |
Galimi Francesco | SVP & Chief Medical Officer | 10/02/2023 | 11,087 |
Healey Don | Chief Technology Officer | 10/02/2023 | 12,425 |
Schor Chen | President & CEO | 10/02/2023 | 31,795 |
Schor Chen | President & CEO | 09/28/2023 | 7,810 |
Schor Chen | President & CEO | 10/02/2023 | 7,340 |
Schor Chen | President & CEO | 09/29/2023 | 7,481 |
Schor Chen | President & CEO | 09/28/2023 | 7,810 |
DUBIN STEVE | Director | 06/30/2023 | 11,999 |
GORDON CARL L | Director | 06/27/2023 | 1,828,750 |
ORBIMED ADVISORS LLC | Director | 06/27/2023 | 1,828,750 |
Healey Don | Chief Technology Officer | 02/15/2023 | 34,327 |
Healey Don | Chief Technology Officer | 02/10/2023 | 83,476 |
Aftab Blake | Chief Scientific Officer | 11/10/2022 | 146,307 |
Schor Chen | President & CEO | 11/10/2022 | 601,920 |
Schor Chen | President & CEO | 11/10/2022 | 209,322 |
Schor Chen | President & CEO | 11/07/2022 | 571,488 |
Schor Chen | President & CEO | 11/02/2022 | 9,000 |
Schor Chen | President & CEO | 11/03/2022 | 447,718 |
Aftab Blake | Chief Scientific Officer | 10/19/2022 | 131,250 |
Aftab Blake | Chief Scientific Officer | 10/13/2022 | 126,293 |
Aftab Blake | Chief Scientific Officer | 10/12/2022 | 25,003 |
Aftab Blake | Chief Scientific Officer | 10/12/2022 | 25,348 |
Schor Chen | President & CEO | 10/04/2022 | 302,715 |
Harvey Brian Nicholas | Chief Financial Officer | 10/04/2022 | 100,905 |
Healey Don | Chief Technology Officer | 10/04/2022 | 112,807 |
Galimi Francesco | SVP & Chief Medical Officer | 10/04/2022 | 112,807 |
Schor Chen | President & CEO | 09/14/2022 | 17,136 |
Schor Chen | President & CEO | 09/13/2022 | 60,713 |
Schor Chen | President & CEO | 09/12/2022 | 1,122,907 |
Schor Chen | President & CEO | 09/09/2022 | 133,601 |
Schor Chen | President & CEO | 08/04/2022 | 388,506 |
Galimi Francesco | SVP & Chief Medical Officer | 08/04/2022 | 100,977 |
Aftab Blake | Chief Scientific Officer | 08/04/2022 | 100,977 |
Harvey Brian Nicholas | Chief Financial Officer | 08/04/2022 | 85,702 |
Healey Don | Chief Technology Officer | 08/04/2022 | 100,977 |
Aftab Blake | Chief Scientific Officer | 08/03/2022 | 125,424 |
Aftab Blake | Chief Scientific Officer | 08/01/2022 | 115,948 |
Aftab Blake | Chief Scientific Officer | 07/05/2022 | 19,764 |
Galimi Francesco | SVP & Chief Medical Officer | 04/04/2022 | 110,956 |
Galimi Francesco | SVP & Chief Medical Officer | 04/01/2022 | 45,497 |
Galimi Francesco | SVP & Chief Medical Officer | 04/04/2022 | 167,559 |
Galimi Francesco | SVP & Chief Medical Officer | 04/01/2022 | 160,041 |
Jakobovits Aya | Director | 03/09/2022 | 56,000 |
Jakobovits Aya | Director | 02/16/2022 | 59,328 |
Healey Don | Chief Technology Officer | 02/14/2022 | 78,956 |
Aftab Blake | Chief Scientific Officer | 02/14/2022 | 78,956 |
Galimi Francesco | SVP & Chief Medical Officer | 02/14/2022 | 78,956 |
Harvey Brian Nicholas | Chief Financial Officer | 02/14/2022 | 67,012 |
Schor Chen | President & CEO | 02/14/2022 | 303,780 |
Galimi Francesco | SVP & Chief Medical Officer | 01/28/2022 | 64,681 |
Healey Don | Chief Technology Officer | 01/28/2022 | 64,681 |
Aftab Blake | Chief Scientific Officer | 01/28/2022 | 65,043 |
Harvey Brian Nicholas | Chief Financial Officer | 01/28/2022 | 54,896 |
Schor Chen | President & CEO | 01/28/2022 | 248,857 |
GORDON CARL L | Director | 12/10/2021 | 2,999,990 |
ORBIMED ADVISORS LLC | Director | 12/10/2021 | 2,999,990 |
Sinclair Andrew | Director | 12/08/2021 | 7,000,000 |
Sinclair Andrew | Director | 12/08/2021 | 7,000,000 |
Schor Chen | President & CEO | 06/16/2021 | 173,443 |
Jakobovits Aya | Director | 06/15/2021 | 42,919 |
Galimi Francesco | SVP & Chief Medical Officer | 06/04/2021 | 41,689 |
Schor Chen | President & CEO | 05/19/2021 | 221,436 |
Schor Chen | President and CEO | 04/20/2021 | 197,676 |
Schor Chen | President and CEO | 04/06/2021 | 214,700 |
Schor Chen | President and CEO | 03/30/2021 | 211,640 |
Schor Chen | President and CEO | 03/16/2021 | 252,558 |
Schor Chen | President and CEO | 03/16/2021 | 252,558 |
Chimovits Erez | Director | 02/12/2021 | 6,816,537 |
GORDON CARL L | Director | 02/12/2021 | 6,816,537 |
ORBIMED ADVISORS LLC | Director | 02/12/2021 | 6,816,537 |
PureTech Health LLC | 10% Owner | 12/18/2019 | 7,393,837 |
PureTech Health LLC | 10% Owner | 12/13/2019 | 255,805 |
PureTech Health LLC | 10% Owner | 12/12/2019 | 482,316 |
PureTech Health LLC | 10% Owner | 12/11/2019 | 74,901 |
PureTech Health LLC | 10% Owner | 12/10/2019 | 423,663 |
PureTech Health LLC | 10% Owner | 11/15/2019 | 661,941 |
Schor Chen | President and CEO | 04/16/2018 | 17,907 |
Schor Chen | President and CEO | 04/11/2018 | 18,724 |
Schor Chen | President and CEO | 04/10/2018 | 16,915 |
SILVERSTEIN JONATHAN | Director | 01/30/2018 | 7,999,995 |
ORBIMED ADVISORS LLC | Director | 01/30/2018 | 7,999,995 |
PureTech Health LLC | 10% Owner | 01/30/2018 | 3,499,995 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 9,772,598 | 0.39% | 17.43% | Other |
BlackRock Inc. | 2,111,898 | 0.00017% | -3.24% | Other |
RENAISSANCE TECHNOLOGIES LLC | 766,600 | 0.00224% | 13.23% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 661,795 | 0.00013% | 4.56% | Other |
D. E. SHAW & CO., INC. | 346,619 | 0.00057% | 41.55% | Other |
AQR CAPITAL MANAGEMENT LLC | 75,022 | 0.00021% | Exited | Other |
BALYASNY ASSET MANAGEMENT L.P. | 12,550 | 0.00004% | Exited | Event Driven |
Period of Report: 12/31/2023
10-K/10-Q Filings: View